A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists (SPARK-CVD)

Novo Nordisk

Status: Completed

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)

Treatments: Other: No treatment given

Study type: Observational

Funder types: Industry

Identifiers

NCT06589791

DAS-8091

U1111-1303-3098 (Other Identifier)

Details and patient eligibility

About

This is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among Chinese cardiologists and nephrologists towards the role of systemic inflammation in patients with ASCVD and CKD in real-world clinical setting.

Enrollment: 1,500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Work in cardiology, internal medicine, or nephrology department
• Specialize in one of the following: coronary interventional cardiology, HF, general cardiology, preventive cardiology, cardiac rehabilitation or nephrology
• Practice at consultant level for 3+ years after standardized training for resident physicians or 3+ years' working experience as a specialist
• Manage at least 20 adult patients with ASCVD and CKD (not dialysis-only) every month

Exclusion criteria

• Unwilling to provide informed consent
• Insufficient number of patients with ASCVD and CKD
• Do not fulfil inclusion criteria.

Trial design

1,500 participants in 1 patient group

Health care professionals

Description:

Cardiologists and nephrologists in China

Treatment:

Other: No treatment given